Company Filing History:

11 out of 1,500

Astrazeneca Ab

patents

2 out of 107

Astra Zeneca U.k. Limited

patents

1 out of 24

Astra Pharmaceuticals Limited

patents

Years Active: 2000-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10053453 - Compounds and their use as BACE inhibitors (2018-08-21),

2. 7297818 - Adamantane derivatives (2007-11-20),

3. 7132457 - Adamantane derivatives (2006-11-07),

4. 6984644 - Treatment of skin disorders using thieno[2,3-D]pyrimidinediones (2006-01-10),

5. 6881754 - Adamantane derivatives (2005-04-19),

6. 6770646 - Substituted fused pyridazinone compounds; composition and use thereof (2004-08-03),

7. 6720452 - Adamantane derivatives (2004-04-13),

8. 6555541 - Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions (2003-04-29),

9. 6469014 - Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy (2002-10-22),

10. 6342601 - Compounds (2002-01-29),

11. 6342502 - Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases (2002-01-29),

12. 6300334 - Thieno[2,3-d]pyrimidine-2,4-diones (2001-10-09),

13. 6180635 - Compounds (2001-01-30),

14. 6028074 - Pyrazolo[3,4-d]pyrimidineone compounds (2000-02-22),

Title: The Innovations of Philip Vellacott Thorne

Introduction

Philip Vellacott Thorne is a notable inventor based in Leicestershire, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work primarily focuses on compounds that serve as BACE inhibitors, which are crucial in the treatment of various cognitive disorders.

Latest Patents

Thorne's latest patents include innovative compounds and their use as BACE inhibitors. These compounds are designed to treat or prevent Aβ-related pathologies, including Down's syndrome and Alzheimer's disease. His research addresses disorders associated with cognitive impairment, such as mild cognitive impairment and various forms of dementia. Another significant patent involves adamantane derivatives, which outlines a process for their preparation and their therapeutic applications.

Career Highlights

Throughout his career, Thorne has worked with prominent companies such as AstraZeneca AB and AstraZeneca UK Limited. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in medical treatments.

Collaborations

Thorne has collaborated with notable professionals in his field, including Martin E. Cooper and Mark Furber. These partnerships have facilitated the exchange of ideas and expertise, enhancing the impact of his work.

Conclusion

Philip Vellacott Thorne's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of cognitive disorders.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com